title: Sunitinib and everolimus in  pancreatic neuroendocrine tumors.
authors: Giuseppe
authors: G
authors: Procopio
authors: Sara
authors: S
authors: Pusceddu
authors: Roberto
authors: R
authors: Buzzoni
mesh_terms: D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004311:Double-Blind Method; D000068338:Everolimus; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013280:Stomatitis / Q000139:chemically induced; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus